For targeted delivery of TLR3 agonist to tumor cells we sought to employ this platform technology and to couple biotinylated nucleic acid-based TLR agonists, in particular dsRNA, to tumor-specific antibodies via consecutive bio-conjugation to neutravidin. The gene discussed is TLR3; the disease is neoplasm.